Eye Drops to Treat Wet AMD

Ohr Pharmaceutical Inc (Nasdaq: OHRP) announced that its Squalamine Eye Drop formulation was awarded Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of the wet form of macular degeneration (wet-AMD).

According to Ohr’s CEO, the Fast Track designation underscores the importance of developing an eye drop designed for self-administration for the treatment of wet-AMD. Clearly, self-administrating eye drops to treat wet AMD is preferable over regular intravitreal injections of Roche/Genentech’s Lucentis(R) or Avastin(R), or Regeneron’s Eylea(R), directly into the eye.

For more info:

http://eyedocnews.com/006675-eye-drop-to-treat-wet-macular-degeneration-granted-fast-track-designation-by-fda/

http://www.ohrpharmaceutical.com/index-2d.html

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: